Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2025
Event: Entry into Material Definitive Agreements (Inducement Letter Agreements) to facilitate the exercise of existing warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Total Expected Gross Proceeds: Approximately $13.4 million (prior to fees and expenses).
- Initial Closing Proceeds: Approximately $12.6 million (closed November 4 and 6, 2025).
- Existing Warrants Exercised: Aggregate of 5,663,182 shares.
- Exercise Prices:
- 60,000 shares at $2.00 per share.
- 948,596 shares at $2.485 per share.
- 4,654,586 shares at a reduced price of $2.05 per share.
- New Warrants Issued: Up to 11,326,364 shares (Series A Warrants).
- New Warrant Terms: Exercise price of $2.05 per share; 24-month term; exercisable immediately.
- Placement Agent Fees (H.C. Wainwright & Co., LLC):
- Cash fee: 7.5% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Warrants: 424,739 Placement Agent Warrants (7.5% of exercised warrants).
- Expenses: $35,000 (non-accountable), $50,000 (accountable), $15,950 (clearing fees).
Material Changes and Transaction Structure
The Company entered into inducement agreements to lower the exercise price of certain existing warrants from ranges between $2.00 and $5.45 down to $2.05 for the majority of the tranche. In exchange for the cash exercise and a payment of $0.125 per new warrant (totaling $1,415,795.50), holders received new warrants to purchase up to 11,326,364 shares. The transaction is structured in multiple tranches, with the initial closings completed in early November 2025 and additional closings expected by November 18, 2025.
Guidance, Outlook, and Risks
- Future Closings: Additional closings are expected by November 18, 2025, involving the exercise of 350,000 existing warrants at $2.05 and the issuance of 700,000 new warrants.
- Registration: The Company agreed to file a resale registration statement for the new warrant shares within 20 calendar days of the agreement date.
- Issuance Restrictions: The Company agreed not to issue or announce the issuance of any common stock or equivalents for 15 calendar days after the closing of the offering, except for the additional closings described.
- Risks/Contingencies: The New Warrants and Placement Agent Warrants were issued unregistered under Section 4(a)(2) and Rule 506 of Regulation D. They may not be offered or sold absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the final closing date and total proceeds once the November 18, 2025 tranche is completed.
- Confirm the filing date and effectiveness of the Resale Registration Statement for the New Warrant Shares.
- Review the dilution impact of the 11,326,364 new warrants and 424,739 placement agent warrants on existing shareholders.
- Monitor the Company's cash position post-closing to assess runway for operations.
- Check for any subsequent amendments to the Inducement Letter Agreements or warrant terms.